Carilex Medical (ROCO:7726) Other Stockholders Equity: NT$40.5 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:7726 Carilex Medical Inc ROCO:7726
33 GF Score
Price NT$32.15
! 5 Warning Signs
View Full Analysis

What is Carilex Medical Other Stockholders Equity?

Carilex Medical ROCO:7726 +4.23% 33 Other Stockholders Equity is NT$40.5 Mil as of Dec. 2025. GuruFocus rates ROCO:7726 with a GF Score™ of 33/100. The stock has 5 warning signs investors should review.

Carilex Medical's Other Stockholders Equity for the quarter that ended in Dec. 2025 was NT$40.5 Mil.

Carilex Medical's quarterly Other Stockholders Equity increased from Dec. 2024 (NT$37.7 Mil) to Jun. 2025 (NT$38.6 Mil) and increased from Jun. 2025 (NT$38.6 Mil) to Dec. 2025 (NT$40.5 Mil).

Carilex Medical's annual Other Stockholders Equity increased from Dec. 2023 (NT$32.2 Mil) to Dec. 2024 (NT$37.7 Mil) and increased from Dec. 2024 (NT$37.7 Mil) to Dec. 2025 (NT$40.5 Mil).

Carilex Medical Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Carilex Medical's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carilex Medical Other Stockholders Equity Chart

Carilex Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial 25.63 29.02 32.20 37.67 40.46

Carilex Medical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.20 37.81 37.67 38.55 40.46
ROCO:7726
33GF Score
Carilex Medical Inc ROCO:7726
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carilex Medical Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of NT$40.5 Mil mean?
Carilex Medical (ROCO:7726) has a Other Stockholders Equity of NT$40.5 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Carilex Medical and its competitors.
Is Carilex Medical's Other Stockholders Equity too high?
Carilex Medical's current Other Stockholders Equity is NT$40.5 Mil. Overall, Carilex Medical has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Carilex Medical's Other Stockholders Equity compare to ABT and SYK?
Carilex Medical's Other Stockholders Equity of NT$40.5 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Medical Devices & Instruments company?
A good Other Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Carilex Medical and its competitors. Carilex Medical's current Other Stockholders Equity is NT$40.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carilex Medical stock overvalued right now?
Carilex Medical (ROCO:7726) has a current Other Stockholders Equity of NT$40.5 Mil. The current Other Stockholders Equity is NT$40.5 Mil. Carilex Medical's overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Carilex Medical (ROCO:7726), the current Other Stockholders Equity is NT$40.5 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Carilex Medical Business Description

Address No.77, Keji 1st Road, Guishan District, Taoyuan, TWN, 33383
Carilex Medical Inc is a company engaged in the wound care industry by developing leading-edge technology in the prevention and treatment of wounds. Their expertise is in research and development, manufacturing, and quality control and assurance allow us to provide unparalleled products in wound care management in the form of comprehensive product lines proven to prevent and manage pressure sores and wounds. They offer products in the form of Support Surfaces, Chair Cushion and Negative Pressure Wound Therapy.
33GF Score

Get the complete analysis for ROCO:7726

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$32.15
Price